JP6948671B2 - Composition for promoting fecal lipid excretion containing D-sorbose as an active ingredient - Google Patents
Composition for promoting fecal lipid excretion containing D-sorbose as an active ingredient Download PDFInfo
- Publication number
- JP6948671B2 JP6948671B2 JP2017127009A JP2017127009A JP6948671B2 JP 6948671 B2 JP6948671 B2 JP 6948671B2 JP 2017127009 A JP2017127009 A JP 2017127009A JP 2017127009 A JP2017127009 A JP 2017127009A JP 6948671 B2 JP6948671 B2 JP 6948671B2
- Authority
- JP
- Japan
- Prior art keywords
- sorbose
- composition
- active ingredient
- feces
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- LKDRXBCSQODPBY-IANNHFEVSA-N D-sorbose Chemical compound OCC1(O)OC[C@@H](O)[C@H](O)[C@H]1O LKDRXBCSQODPBY-IANNHFEVSA-N 0.000 title claims description 30
- 150000002632 lipids Chemical class 0.000 title claims description 16
- 230000029142 excretion Effects 0.000 title claims description 13
- 239000000203 mixture Substances 0.000 title claims description 13
- 230000002550 fecal effect Effects 0.000 title claims description 9
- 230000001737 promoting effect Effects 0.000 title claims description 7
- 239000004480 active ingredient Substances 0.000 title claims description 6
- 108020004999 messenger RNA Proteins 0.000 claims description 8
- 108010045374 CD36 Antigens Proteins 0.000 claims description 7
- 238000010521 absorption reaction Methods 0.000 claims description 4
- 230000037396 body weight Effects 0.000 claims description 4
- 210000000813 small intestine Anatomy 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 102000049320 CD36 Human genes 0.000 claims 1
- 210000003608 fece Anatomy 0.000 description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- 235000014113 dietary fatty acids Nutrition 0.000 description 11
- 239000000194 fatty acid Substances 0.000 description 11
- 229930195729 fatty acid Natural products 0.000 description 11
- 150000004665 fatty acids Chemical class 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 9
- BJHIKXHVCXFQLS-PUFIMZNGSA-N D-psicose Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)C(=O)CO BJHIKXHVCXFQLS-PUFIMZNGSA-N 0.000 description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 102000053028 CD36 Antigens Human genes 0.000 description 6
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 6
- LKDRXBCSQODPBY-OEXCPVAWSA-N D-tagatose Chemical compound OCC1(O)OC[C@@H](O)[C@H](O)[C@@H]1O LKDRXBCSQODPBY-OEXCPVAWSA-N 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- RFSUNEUAIZKAJO-VRPWFDPXSA-N D-Fructose Natural products OC[C@H]1OC(O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-VRPWFDPXSA-N 0.000 description 4
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000004584 weight gain Effects 0.000 description 4
- 235000019786 weight gain Nutrition 0.000 description 4
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 3
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 3
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 3
- 239000005642 Oleic acid Substances 0.000 description 3
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000002224 dissection Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 210000001596 intra-abdominal fat Anatomy 0.000 description 3
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 101150112561 CD36 gene Proteins 0.000 description 2
- BJHIKXHVCXFQLS-PYWDMBMJSA-N D-sorbose group Chemical group OCC(=O)[C@H](O)[C@@H](O)[C@H](O)CO BJHIKXHVCXFQLS-PYWDMBMJSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- KJFMBFZCATUALV-UHFFFAOYSA-N phenolphthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2C(=O)O1 KJFMBFZCATUALV-UHFFFAOYSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- BJHIKXHVCXFQLS-UYFOZJQFSA-N D-fructose group Chemical group OCC(=O)[C@@H](O)[C@H](O)[C@H](O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 description 1
- -1 D-sorbose Chemical class 0.000 description 1
- BJHIKXHVCXFQLS-PQLUHFTBSA-N D-tagatose group Chemical group OCC(=O)[C@@H](O)[C@@H](O)[C@H](O)CO BJHIKXHVCXFQLS-PQLUHFTBSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000007976 Ketosis Diseases 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 150000002584 ketoses Chemical class 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 102000014452 scavenger receptors Human genes 0.000 description 1
- 108010078070 scavenger receptors Proteins 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
本発明は、Ｄ−ソルボースを有効成分として含有する糞便脂質排泄促進用組成物に関する。 The present invention relates to a composition for promoting fecal lipid excretion containing D-sorbose as an active ingredient.
Ｄ−ソルボースは、甘味度が砂糖の約７０％であって、体重増加抑制作用、内臓脂肪蓄積改善作用、体脂肪蓄積改善作用、プレバイオティックス作用、血清尿酸値低減作用、肝機能改善作用、糖代謝改善作用（以上、特許文献１）及び２糖類分解酵素阻害による食後血糖低下作用（特許文献２）が知られている。 D-sorbose has a sweetness of about 70% of that of sugar, and has an effect of suppressing weight gain, an effect of improving visceral fat accumulation, an effect of improving body fat accumulation, a prebiotic effect, an effect of reducing serum uric acid level, and an effect of improving liver function. The action of improving glucose metabolism (above, Patent Document 1) and the action of lowering postprandial blood glucose by inhibiting disaccharide-degrading enzyme (Patent Document 2) are known.
上述のとおり、Ｄ−ソルボースの各種機能は知られているが、その詳細や上記以外の機能は未だ不明であり、その解明が待たれるところであった。 As mentioned above, various functions of D-sorbose are known, but the details and functions other than the above are still unknown, and their elucidation has been awaited.
本発明者らは、Ｄ−ソルボースについて種々検討したところ、意外にも、Ｄ−ソルボースが糞便への脂質排泄を促進することを見出し、本発明を完成するに至った。Ｄ−ソルボースと同じくケトースに属するＤ−プシコースが、体重増加抑制作用や血糖値上昇抑制作用を有するにもかかわらず、糞便脂質排泄はほとんど促進しないことからすると、予測できないことであった。 As a result of various studies on D-sorbose, the present inventors have surprisingly found that D-sorbose promotes lipid excretion into feces, and have completed the present invention. It was unpredictable because D-psicose, which belongs to ketose like D-sorbose, has an effect of suppressing weight gain and an effect of suppressing increase in blood glucose level, but hardly promotes fecal lipid excretion.
すなわち、本発明は、上記知見に基づき完成されたものであり、以下の［１］〜［４］から構成されるものである。
［１］ Ｄ−ソルボースを有効成分として含有する、糞便脂質排泄促進用の組成物。
［２］小腸の脂質吸収関連遺伝子であるＣＤ３６のｍＲＮＡの発現量を減少させることを特徴とする上記［１］記載の組成物。
［３］１回あたりＤ‐ソルボースが０．０６〜０．１ｇ／ｋｇ体重として摂取されるように用いられることを特徴とする、請求項１又は２に記載の組成物。
［４］Ｄ−ソルボースを経口摂取する工程を含む、糞便への脂質排泄を促進する方法。
That is, the present invention has been completed based on the above findings, and is composed of the following [1] to [4].
[1] A composition for promoting fecal lipid excretion, which contains D-sorbose as an active ingredient.
[2] The composition according to the above [1], which is characterized by reducing the expression level of mRNA of CD36, which is a gene related to lipid absorption in the small intestine.
[3] The composition according to claim 1 or 2, wherein D-sorbose is used so as to be ingested as 0.06 to 0.1 g / kg body weight per dose.
[4] A method for promoting lipid excretion into feces, which comprises a step of ingesting D-sorbose orally.
本発明のＤ−ソルボースを含有する組成物を摂取すれば、糞便への脂質排泄を促進することができる。 Ingestion of the composition containing D-sorbose of the present invention can promote the excretion of lipids into feces.
本発明におけるＤ−ソルボースは、もっとも簡便には、Ｄ−フラクトースを原料に酵素（エピメラーゼ）によって生産されるが、酵素的に生産されたものに限らず、化学的に生産されたものでもよい。また、本発明におけるＤ−ソルボースは、混合品、純品のいずれの形態でも使用することができ、混合品としては、例えば、「レアシュガースウィート」（松谷化学工業株式会社製）があり、これを使用することもできる。 The D-sorbose in the present invention is most simply produced by an enzyme (epimerase) using D-fructose as a raw material, but it is not limited to the enzymatically produced one, and may be chemically produced. Further, the D-sorbose in the present invention can be used in either a mixed product or a pure product form, and examples of the mixed product include "rare sugar sweet" (manufactured by Matsutani Chemical Industry Co., Ltd.). Can also be used.
本発明における「糞便脂質」とは、体外へ排出された糞便中の脂質を指し、後述する方法により測定できる。また、「排泄促進」とは、糞便脂質の量が、Ｄ−ソルボースを含有しない食餌を摂取したときより多い状態を指す。 The "fecal lipid" in the present invention refers to the lipid in feces excreted from the body, and can be measured by the method described later. In addition, "promotion of excretion" refers to a state in which the amount of fecal lipid is higher than that when a diet containing no D-sorbose is ingested.
本発明のＤ−ソルボースを有効成分として含有する組成物中のＤ−ソルボースの含量は特に限定されないが、好ましくは１〜１００質量％である。また、有効成分としてのＤ−ソルボースの摂取量は、１回あたり０．０２〜０．２ｇ／ｋｇ体重が好ましく、０．０６〜０．１ｇ／ｋｇ体重がより好ましい。 The content of D-sorbose in the composition containing D-sorbose of the present invention as an active ingredient is not particularly limited, but is preferably 1 to 100% by mass. The intake of D-sorbose as an active ingredient is preferably 0.02 to 0.2 g / kg body weight, and more preferably 0.06 to 0.1 g / kg body weight.
以下、実施例により本発明を具体的に説明するが、これらによって本発明が限定されるものではない。 Hereinafter, the present invention will be specifically described with reference to Examples, but the present invention is not limited thereto.
（ラットの飼育）
５週齢の雄性Ｓｐｒａｇｕｅ−Ｄａｗｌｅｙラット３２匹を、コントロール摂取群、３％Ｄ−ソルボース摂取群、３％Ｄ−フラクトース摂取群、３％Ｄ−プシコース摂取群及び３％Ｄ−タガトース摂取群の５群（１群あたり６匹又は７匹）に分け、実験飼料と水を自由摂取として４週間飼育し、解剖を行った。なお、与えた餌の組成は表１に示す。
(Rat breeding)
Thirty-two 5-week-old male Sprague-Dawley rats were taken in a control group, a 3% D-sorbose group, a 3% D-fructose group, a 3% D-psicose group, and a 3% D-tagatose group. The animals were divided into groups (6 or 7 animals per group), and were bred for 4 weeks with free intake of experimental feed and water, and dissected. The composition of the fed food is shown in Table 1.
（臓器等重量の測定）
上記飼育後、解剖前２日間の糞を採取して凍結乾燥した後の重量を測定した。その重量を表４に示す。また、解剖時に採血を行うとともに肝臓及び体脂肪を採取し、その重量を測定した。表２に体重増加量及び腹腔内脂肪重量を示す。
(Measurement of weight of organs, etc.)
After the above breeding, feces were collected for 2 days before dissection and weighed after freeze-drying. The weight is shown in Table 4. In addition, blood was collected at the time of dissection, and liver and body fat were collected and their weights were measured. Table 2 shows the amount of weight gain and the weight of intraperitoneal fat.
（中性脂肪の測定）
血清中性脂肪は、市販のキット（トリグリセライド Ｅテストワコー、和光純薬工業株式会社）を用いて測定した。また、肝臓中性脂肪は、肝臓脂質を有機溶媒により抽出後、同キットを用いて測定した。血清中性脂肪及び肝臓中性脂肪量を表３に示す。
(Measurement of triglycerides)
Serum triglyceride was measured using a commercially available kit (Triglyceride E Test Wako, Wako Pure Chemical Industries, Ltd.). The hepatic triglyceride was measured using the same kit after extracting the hepatic lipid with an organic solvent. Table 3 shows the amounts of triglyceride in serum and triglyceride in liver.
（糞中脂肪酸量の測定）
糞中の脂肪酸量は、Ｊｅｅｊｅｅｂｈｏｙらの方法に準じて行った。具体的には、凍結乾燥粉砕した糞を共栓付広口試験管に秤量して塩酸を２滴滴下し、ヘプタン：ジエチルエーテル：９５％エタノール（１：１：１）の混合液を加えて振とう混合した。次に、これを室温で遠心後、上層を別の共栓付広口試験管に採取した。２回目以降の抽出はヘプタン：ジエチルエーテル：９５％エタノール：脱イオン水混合液（１：１：１：１）で行い、計３回の抽出作業を行った。得られた上層画分は窒素乾固してヘキサンに溶解後、半量を窒素乾固し、１Ｎ水酸化ナトリウム−９０％エタノール溶液を加えて混合後、７５Ｃ・１時間のケン化を行った。ｐＨ試験紙でｐＨ３以下であることを確認した後、ヘプタン：ジエチルエーテル：９５％エタノール：脱イオン水混合液（１：１：１：１）を加え、脂肪酸を抽出した。室温でこれを遠心し、上層を別の共栓付広口試験管に採取した。この抽出作業を繰り返し、集めた上層を窒素乾固後、エタノールを加えた。フェノールフタレインを指示薬として３〜４滴加え、０．０２Ｎ水酸化ナトリウムで滴定を行った。なお、滴定の盲検にはエタノール３ｍＬ、標準液には０．１ｍｍｏｌオレイン酸を３ｍＬのエタノールに溶解したものを使用した。標準オレイン酸の滴定値をオレイン酸量とし、サンプリングした２日間の糞重量から１日当たりの脂肪酸量を算出した。表４に、糞重量と糞中脂肪酸排泄量を示す。
(Measurement of fatty acid content in feces)
The amount of fatty acid in feces was determined according to the method of Jejeebhoy et al. Specifically, the lyophilized and crushed feces are weighed in a wide-mouthed test tube with a stopper, 2 drops of hydrochloric acid are added dropwise, and a mixed solution of heptane: diethyl ether: 95% ethanol (1: 1: 1) is added and shaken. Finally mixed. Next, this was centrifuged at room temperature, and the upper layer was collected in another wide-mouthed test tube with a stopper. The second and subsequent extractions were carried out with a mixture of heptane: diethyl ether: 95% ethanol: deionized water (1: 1: 1: 1), and the extraction work was carried out a total of three times. The obtained upper layer fraction was dried with nitrogen and dissolved in hexane, half of the fraction was dried with nitrogen, a 1N sodium hydroxide-90% ethanol solution was added and mixed, and then saponification was carried out at 75 C for 1 hour. After confirming that the pH was 3 or less with pH test paper, a mixed solution of heptane: diethyl ether: 95% ethanol: deionized water (1: 1: 1: 1) was added to extract fatty acids. This was centrifuged at room temperature, and the upper layer was collected in another wide-mouthed test tube with a stopper. This extraction operation was repeated, and the collected upper layer was dried with nitrogen, and then ethanol was added. Phenolphthalein was added as an indicator in 3 to 4 drops, and titration was performed with 0.02N sodium hydroxide. For the blinding of titration, 3 mL of ethanol was used, and as the standard solution, 0.1 mmol oleic acid dissolved in 3 mL of ethanol was used. The titrated value of standard oleic acid was used as the amount of oleic acid, and the amount of fatty acid per day was calculated from the weight of the sampled feces for 2 days. Table 4 shows the weight of feces and the amount of fatty acid excreted in feces.
（ＣＤ３６ｍＲＮＡの測定）
ＣＤ３６遺伝子は、脂肪酸の取り込みに関与するスカベンジャー受容体であるため、そのｍＲＮＡの発現量が低下すれば、糞便への脂質排泄が促進されていることの裏づけとなりうる。そこで、ＣＤ３６ｍＲＮＡの発現量をＲＴ−ＰＣＲ法にて測定した。その結果を表５に示す。
(Measurement of CD36 mRNA)
Since the CD36 gene is a scavenger receptor involved in fatty acid uptake, a decrease in the expression level of its mRNA may support the promotion of lipid excretion into feces. Therefore, the expression level of CD36 mRNA was measured by the RT-PCR method. The results are shown in Table 5.
（結果及び考察）
ラット解剖時の体重増加量は、すべての群間において有意な差は認められなかった。一方、腹腔内脂肪重量は、コントロール摂取群と比較して、Ｄ−フラクトース摂取群では増加し、Ｄ−ソルボース摂取群、Ｄ−プシコース摂取群及びＤ−タガトース摂取群では減少した（以上、表２）。
(Results and discussion)
There was no significant difference in weight gain at rat dissection between all groups. On the other hand, the intra-abdominal fat weight increased in the D-fructose intake group and decreased in the D-sorbose intake group, the D-psicose intake group and the D-tagatose intake group as compared with the control intake group (the above, Table 2). ).
血清中性脂肪は、コントロール摂取群と比較して、Ｄ−ソルボース摂取群でのみ有意に減少した。また、肝臓中性脂肪は、コントロール群と比較して、Ｄ−ソルボース摂取群及びＤ−タガトース摂取群でやや減少した（以上、表３）。 Serum triglyceride was significantly reduced only in the D-sorbose intake group compared to the control intake group. In addition, triglyceride in the liver was slightly reduced in the D-sorbose intake group and the D-tagatose intake group as compared with the control group (Table 3 above).
糞重量は、コントロール摂取群と比較して、Ｄ−ソルボース摂取群では増加し、Ｄ−フラクトース摂取群、Ｄ−プシコース摂取群及びＤ−タガトース摂取群では減少した。また、糞中への脂肪酸排泄量は、コントロール摂取群と比較して、Ｄ−ソルボース摂取群では顕著に増加したが、Ｄ−プシコース摂取群及びＤ−タガトース摂取群では減少した（以上、表４）。 Fecal weight increased in the D-sorbose intake group and decreased in the D-fructose intake group, D-psicose intake group and D-tagatose intake group as compared with the control intake group. In addition, the amount of fatty acid excreted in feces increased significantly in the D-sorbose intake group as compared with the control intake group, but decreased in the D-psicose intake group and the D-tagatose intake group (above, Table 4). ).
ＣＤ３６ｍＲＮＡは、コントロール摂取群と比較して、Ｄ−ソルボース摂取群及びＤ−プシコース摂取群で減少した。Ｄ−プシコース群では、糞中への脂肪酸排泄量は減少していたことから、ＣＤ３６遺伝子は当該効果に関与していないといえる。一方、Ｄ−ソルボース群では、糞便への脂肪酸排泄量が顕著に増加していることから、Ｄ−ソルボースは、脂肪吸収に関与するＣＤ３６ｍＲＮＡの発現低下を介して、脂肪酸の小腸への吸収を抑制している可能性が考えられた（以上、表５）。 CD36 mRNA was reduced in the D-sorbose and D-psicose groups compared to the control group. In the D-psicose group, the amount of fatty acid excreted in feces was reduced, so it can be said that the CD36 gene is not involved in the effect. On the other hand, in the D-sorbose group, the amount of fatty acid excreted in feces was remarkably increased, so that D-sorbose suppressed the absorption of fatty acids into the small intestine through a decrease in the expression of CD36 mRNA involved in fat absorption. It was considered possible that this was the case (Table 5 above).
以上の結果から、Ｄ−フラクトース、Ｄ−プシコース、Ｄ−タガトース及びＤ−ソルボースのうち、Ｄ−ソルボースのみが、腹腔内脂肪重量及び肝臓中性脂肪を減少させるだけでなく、血清中性脂肪をも有意に減少させることがわかった。そして、Ｄ−ソルボースは、ＣＤ３６ｍＲＮＡの発現量を低下させ、糞中へ脂肪酸排泄を有意に促進することがわかった。
よって、Ｄ−ソルボースは、ケトースのなかでも、特に効果的に糞中への脂肪排泄を促進する効果を有すると考えられ、有意に糞便脂質排泄促進用の組成物として利用できる。
From the above results, among D-fructose, D-psicose, D-tagatose and D-sorbose, only D-sorbose not only reduces intra-abdominal fat weight and triglyceride in the liver, but also produces serum triglyceride. Was also found to be significantly reduced. It was found that D-sorbose reduces the expression level of CD36 mRNA and significantly promotes fatty acid excretion into feces.
Therefore, D-sorbose is considered to have an effect of promoting fat excretion into feces particularly effectively among kets, and can be significantly used as a composition for promoting fecal lipid excretion.
Claims (3)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017127009A JP6948671B2 (en) | 2017-06-29 | 2017-06-29 | Composition for promoting fecal lipid excretion containing D-sorbose as an active ingredient |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017127009A JP6948671B2 (en) | 2017-06-29 | 2017-06-29 | Composition for promoting fecal lipid excretion containing D-sorbose as an active ingredient |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019011258A JP2019011258A (en) | 2019-01-24 |
| JP6948671B2 true JP6948671B2 (en) | 2021-10-13 |
Family
ID=65227362
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017127009A Active JP6948671B2 (en) | 2017-06-29 | 2017-06-29 | Composition for promoting fecal lipid excretion containing D-sorbose as an active ingredient |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP6948671B2 (en) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5598643B2 (en) * | 2005-09-30 | 2014-10-01 | 長崎県公立大学法人 | Disaccharide hydrolase activity inhibitor |
| JP2009269887A (en) * | 2008-05-09 | 2009-11-19 | Kagawa Univ | Peritoneal deterioration inhibitor containing rare saccharide, peritoneal dialytic fluid and method for peritoneal dialysis |
| JP5706142B2 (en) * | 2010-04-28 | 2015-04-22 | 株式会社ファンケル | Blood glucose lowering agent, visceral fat accumulation inhibitor, TG lowering agent, faecal fat excretion promoter containing ethanol extract of Fuyubodaiju flower as an active ingredient |
| KR101692033B1 (en) * | 2015-09-01 | 2017-01-03 | 경북대학교 산학협력단 | Composition comprising D-psicose for preventing or treating lipid-related metabolic disease |
-
2017
- 2017-06-29 JP JP2017127009A patent/JP6948671B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019011258A (en) | 2019-01-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Giri et al. | Effects of bioactive substance from turmeric on growth, skin mucosal immunity and antioxidant factors in common carp, Cyprinus carpio | |
| Tan et al. | Effects of dietary ginkgo biloba leaf extract on growth performance, plasma biochemical parameters, fish composition, immune responses, liver histology, and immune and apoptosis-related genes expression of hybrid grouper (Epinephelus lanceolatus♂× Epinephelus fuscoguttatus♀) fed high lipid diets | |
| Song et al. | Ethanol extract from Ulva prolifera prevents high‐fat diet‐induced insulin resistance, oxidative stress, and inflammation response in mice | |
| CN102524536A (en) | Application of theaflavin as feed additive and corresponding feed | |
| Jia et al. | Evaluation of silymarin extract from Silybum marianum in mice: anti-fatigue activity | |
| Bringhenti et al. | An early fish oil-enriched diet reverses biochemical, liver and adipose tissue alterations in male offspring from maternal protein restriction in mice | |
| JP2023157951A (en) | Composition for improving liver function | |
| JP6948671B2 (en) | Composition for promoting fecal lipid excretion containing D-sorbose as an active ingredient | |
| CN111419901B (en) | New use of magnoliside to improve gastrointestinal function | |
| KR100919323B1 (en) | A method for preparing extract for the prevention and treatment of hyperlipidemia and obesity from the extract of aster spathulifolius aerial part and composition containing the same | |
| TWI824608B (en) | Use of Taiwan Quinoa Husk Extract to Improve Metabolic Diseases and Regulate Intestinal Bacteria | |
| JP6107328B2 (en) | Propolis / quercetin-containing composition with enhanced anti-inflammatory action | |
| JP5605023B2 (en) | 4-vinylphenol compounds | |
| KR20180000136A (en) | Health food for man climacterium improvement comprising garlic, scallion, wild chive, ginger, chive and pharmaceutical composition for preventing and treating man climacterium | |
| CN112931726A (en) | Functional feed for improving quality of multi-scale white soft-shelled turtles by utilizing schizochytrium limacinum residues | |
| JP5326348B2 (en) | Phthalide derivatives and anti-obesity agents | |
| Chen et al. | Glutathione and astaxanthin: Both enhance antioxidant capacity and regulate lipid metabolism in Pacific white shrimp (Litopenaeus vannamei) fed with high-lipid diets | |
| JP2012171905A (en) | Agent for ameliorating fatty liver by using buckwheat chaff extract as active ingredient | |
| JP2007131603A (en) | L-carnitine synthesis system enzyme gene transcription-promoting composition | |
| Sridhar et al. | Evaluation of carvacrol in ameliorating aflatoxin induced changes with reference to growth and oxidative stress in broiler chickens | |
| JP2010235524A (en) | Antihistamine containing pollen cargo | |
| JP2025077505A (en) | Muscle weakness inhibitors | |
| JP2006151875A (en) | Lipase inhibitor | |
| JP2005325029A (en) | Composition for inhibiting blood glucose level elevation, or the like, health food/anti-diabetes agent by using the same and method for producing composition for inhibiting blood glucose level elevation, or the like | |
| JP2009000015A (en) | Food composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200603 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210607 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210607 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210907 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210909 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6948671 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |